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Human cytomegalovirus (HCMV) exhibits a highly restricted host range. In this study, we sought to examine
the relative significance of host and viral factors in activating early gene expression of the HCMV UL54 (DNA
polymerase) promoter in murine cells. Appropriate activation of the UL54 promoter at early times is essential
for viral DNA replication. To study how the HCMV UL54 promoter is activated in murine cells, a transgenesis
system based on yeast artificial chromosomes (YACs) was established for HCMV. A 178-kb YAC, containing
a subgenomic fragment of HCMV encompassing the majority of the unique long (UL) region, was constructed
by homologous recombination in yeast. This HCMV YAC backbone is defective for viral growth and lacks the
major immediate-early (IE) gene region, thus permitting the analysis of essential cis-acting sequences when
complemented in trans. To quantitatively measure the level of gene expression, we generated HCMV YACs
containing a luciferase reporter gene inserted downstream of either the UL54 promoter or, as a control for late
gene expression, the UL86 promoter, which directs expression of the major capsid protein. To determine the
early gene activation pathway, point mutations were introduced into the inverted repeat 1 (IR1) element of the
UL54 promoter of the HCMV YAC. In the transgenesis experiments, HCMV YACs and derivatives generated
in yeast were introduced into NIH 3T3 murine cells by polyethylene glycol-mediated fusion. We found that
infection of YAC, but not plasmid, transgenic lines with HCMV was sufficient to fully recapitulate the UL54
expression program at early times of infection, indicating the importance of remote regulatory elements in
influencing regulation of the UL54 promoter. Moreover, YACs containing a mutant IR1 in the UL54 promoter
led to reduced (;30-fold) reporter gene expression levels, indicating that HCMV major IE gene activation of
the UL54 promoter is fully permissive in murine cells. In comparison with HCMV, infection of YAC transgenic
NIH 3T3 lines with murine cytomegalovirus (MCMV) resulted in lower (more than one order of magnitude)
efficiency in activating UL54 early gene expression. MCMV is therefore not able to fully activate HCMV early
gene expression, indicating the significance of virus over host determinants in the cross-species activation of
key early gene promoters. Finally, these studies show that YAC transgenesis can be a useful tool in functional
analysis of viral proteins and control of gene expression for large viral genomes.
Human cytomegalovirus (HCMV) is a ubiquitous pathogen
that causes severe disease in newborns and immunosuppressed
patients. The expression of HCMV genes upon infection is
temporally regulated. The first genes expressed (immediate-
early [IE] genes) are independent of any de novo protein
synthesis and encode mainly either regulatory or immune-
modulator factors (1, 11, 20). The regulatory IE genes, to-
gether with cellular host factors, coordinate the next level of
gene expression (early [E] genes). The E genes are dependent
on the viral IE proteins and contribute an essential source of
factors, including viral DNA replication and repair enzymes
and other nonstructural proteins. Late (L) genes are essentially
expressed after the onset of viral DNA replication and con-
tribute primarily to the assembly and morphogenesis of the
virus (6).
Activation of the UL54 (DNA polymerase) promoter at
early times is essential for DNA replication; accordingly, the
UL54 promoter is one of the most intensely studied E gene
promoters of HCMV. A number of factors involved in regu-
lating viral E gene expression have been identified, these pri-
marily being the major IE genes, IE1 and IE2 (UL122-3), and
the UL36-38, IRS1-TRS1, and UL112-113 gene products. The
precise control of temporal gene regulation in HCMV is not
clearly understood. Analysis of the UL54 promoter and up-
stream region revealed that a single element (inverted repeat 1
[IR1]) is primarily responsible for the major IE-mediated ac-
tivation of the promoter (13, 14). IE2 (IE86), a sequence-
specific DNA binding protein, but not IE1 (IE72), is necessary
and sufficient for activation of the UL54 promoter (24). IE2
apparently does not bind directly to IR1 but rather mediates
the transcriptional activation of cellular factors bound to IR1.
Recent studies have shown that the transcription factor Sp1
binds to IR1 and may potentially recruit IE86 to the UL54
promoter (18, 25). Thus, IE2 and probably the UL112-113 and
IRS1-TRS1 gene products may directly or indirectly work as
coactivators of the Sp1 protein on the IR1 element of the
UL54 promoter. The function, if any, of coactivation in the
transcription of UL54 is not known.
HCMV exhibits a highly restricted host range. This strict
species specificity, the reason for which is not known, has
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hampered the development of suitable animal model systems
for HCMV. Murine cells are known to be competent for in-
fection by HCMV but are apparently restricted in the ability to
replicate viral templates (10, 17). It has often been assumed
that inappropriate levels of gene activation of key E genes,
necessary for viral replication, may be in part responsible for
the inability of the virus to replicate (5). Thus, an understand-
ing of the species restriction of HCMV requires determining
the relative importance of virus versus cellular factors in gov-
erning cross-species activation of its key viral E genes. A better
understanding of the species restriction of CMV may lead to
new ways of overcoming limitations in crossing the species
barrier.
In this study, we used a novel genetic system based on yeast
artificial chromosomes (YACs) to examine the transcriptional
activation of the UL54 promoter in murine cells. The findings
of our study show that optimal E gene activation of the UL54
promoter is fully permissible in murine cells and that murine
cells contain host factors necessary for coordinating activation
of HCMV E gene expression by the viral master regulator
(IE2/IE86), indicating that the species restriction likely occurs
downstream of HCMV E gene activation. Markedly, activation
of UL54 was found to be strictly virus species restricted, show-
ing the dominance of virus over host factors in the cross-
species activation.
MATERIALS AND METHODS
Yeast, cells, and virus. Saccharomyces cerevisiae strain YPH857 (Mata ura3-52
lys2-801 ade2-101 his3D200 trp1D63 leu2D1 cyh2R) and derivatives were grown in
standard media (9). Murine NIH 3T3 fibroblasts (ATCC CRL 1658) were prop-
agated in Dulbecco’s modified Eagle medium (DMEM) supplemented with 2
mM glutamine, 100 U of penicillin per ml, 100 mg of gentamicin per ml, and 10%
calf serum. Human foreskin fibroblasts (HFF cells) were cultured in DMEM as
above, except with 10% fetal bovine serum. The AD169 and Towne strains of
HCMV (ATCC VR-538 and VR-977, respectively) and the Smith strain of
murine CMV (MCMV; ATCC VR-1399) were used.
Plasmid constructs. pRML1 and pRML2 were used to create a series of right-
and left-arm plasmids, respectively, of the YACs (23). pRML11I2, the right-arm
plasmid, was constructed in three steps. First, an EcoRI fragment from cosmid
pCM1035 (22), containing the last 7,297 bp of the 39 end of HCMV plus the first
3,967 bp of the 59 end, was cloned into pBluescript-SK (Stratagene, La Jolla,
Calif.), yielding pBS-SK-I1. This plasmid was digested with NotI and self-ligated,
creating pBS-SK1I and -I2. The NotI-ClaI fragment from pBS-SK1I2 was pu-
rified and ligated to pRML1 (23) to construct pRML11I2. This plasmid has
4,895 bp of the 59 end of HCMV. pRML2(ura)1Ea, the left-arm plasmid, was
constructed by cloning a 3,292-bp EcoRI fragment (nucleotide positions 175524
to 178816 in the HCMV genome; GenBank accession number X17403) from
cosmid pCM1050 into pRML2 (22, 23). YPH857 has the appropriate auxotro-
phies to select for both YAC arm plasmids. To construct pRML2-Leu2-PUR, the
PvuII-BamHI 1.4-kb DNA fragment from pPUR was inserted into the blunt-
ended BamHI site of pRML2-Leu2 (Leu2 is a yeast protein involved in the
synthesis of leucine, which complements the leu2 mutation of YPH857), gener-
ating pRML2/D. Then the yeast LEU2 gene was cloned in the place of URA3 as
a HindIII DNA fragment. To develop a mutagenesis shuttle plasmid in which to
clone the different promoters, we generated pLHN. This plasmid has the yeast
HIS3 gene as a selectable marker in yeast, the neomycin resistance gene for
selection in mammalian cells, and the luciferase gene as a reporter. The pro-
moter sequence and the 39 end of the targeted gene were both cloned, flanking
the unique SmaI restriction site. pLHN.UL54wt was constructed as follows. A
445-bp DNA fragment from the UL54 promoter (nucleotide positions 80996
through 81441 of the HCMV genome), present in plasmid pPolCAT (24), and
viral DNA fragment from the 39 region of UL54 (nucleotide positions 77291
through 77516) were cloned into the multicloning site of pLHN, leaving a unique
SmaI site between them. Digestion with SmaI directs recombination to the UL54
locus. pLHN.UL54IRM was constructed by cloning the mutated EcoRI-SmaI
DNA fragment (see “IRM mutagenesis,” below) into EcoRI-SmaI-digested
pLHN.UL54wt, replacing the wild-type (wt) fragment with the mutant one. PCR
was used to test the correct integration of pLHN.UL54wt into the viral sequences
of Y24P. Two oligonucleotides were used: YAC54.2 (TCGCCCTGGATATCG
ACCCGCT), complementary to a region of the UL54 promoter outside the one
included in plasmid pLHN.UL54wt; and GLprimer2 (CTTTATGTTTTTGGC
GTCTTCCA), complementary to the 59 region of the luciferase gene. pLHN.UL86
was constructed as follows. A 432-bp DNA fragment, encompassing the UL86
promoter (nucleotide positions 128318 through 128750 of the HCMV genome),
was cloned along with a 522-bp DNA fragment from the 39-end fragment of the
UL86 gene (nucleotide positions 124981 through 125503), with a SmaI site
between them (Figure 2A). PCR was used to test the correct integration of
pLHN.UL86 into the viral sequences of Y24P. The oligonucleotides used were
YAC86.2 (GTAGCCGGAGACGGCGGTT), complementary to a region of the
UL86 outside the one included in the plasmid pLHN.UL86, and GLprimer2.
PFGE. For the separation of yeast chromosomes, we used a Biometra Rota-
phor R 23. The yeast DNA samples, agarose gels, and pulsed-field gel electro-
phoresis (PFGE) conditions were as directed by the manufacturer. To separate
Y24, an artificial chromosome of approximately 180 kb, we used a 20-h run at 180
V, with 15-s intervals and a rotation angle of 120°.
STS analysis. Specific pairs of primers were designed along the HCMV se-
quence, with an approximate spacing between them of 20 kb, to allow for
checking the intactness of the viral genome. A subset of those sequence-tagged
site (STS) pairs was used in this study see Fig. 2). PCR was performed using
either yeast total DNA of a strain containing Y24 or DNA extracted from
HCMV AD169 as a positive control. Each PCR mixture contained 100 ng of
template DNA and 25 pmol of each oligonucleotide of the STS pair in a total
volume of 25 ml, using standard PCR conditions. The reactions were performed
as follows: 1 cycle at 94°C for 3 min, followed by 30 cycles of amplification for 30 s
at 94°C, 1 min at 50°C, and 1 min at 72°C. An aliquot of the reaction mixture was
loaded in a 1% agarose gel to check for the presence of the expected DNA
fragment size. The pair S22 (oligonucleotides S225 [ATGAGGATCGCGACA
G] and S223 [CGTTATCCGTTCCTCG]; positions 3809 and 4186, respectively,
in the HCMV genome) amplifies a DNA fragment of 378 bp; the pair S04
(oligonucleotides S045 [AGATGGATTCGTGCAC] and S043 [ATCGATCTG
GAGCACT]; positions 36489 and 36714, respectively) amplifies a DNA frag-
ment of 226 bp; the pair S06 (oligonucleotides S065 [GGTCCGCAACTTCTG
ATCCA] and S063 [CAGATCAGTCCACAGGTTCT]; positions 66701 and
67183, respectively) amplifies a fragment of 483 bp; the pair S08 (oligonucleo-
tides S085 [ACGCAGGTGAATATCC] and S083 [AGGTTATCGTCAAGCG];
positions 84721 and 85094, respectively) amplifies a DNA fragment of 374 bp;
the pair S10 (oligonucleotides S105 [GATGGTGGAAATCGGA] and S103
[ATATCGCACCGATTGC]; positions 128975 and 129337, respectively) ampli-
fies a DNA fragment of 363 bp; the pair S12 (oligonucleotides S125 [GTTGG
CGTTGAGCACGTCTA] and S123 [AGCCGACAACCTGCTGCACT]; posi-
tions 149371 and 149770, respectively) amplifies a DNA fragment of 400 bp.
IRM mutagenesis. The mutagenesis of IR1 in the UL54 promoter was done as
previously described (13), using a QuickChange site-directed mutagenesis kit
(Stratagene, La Jolla, Calif.) as instructed by the manufacturer. Briefly, 50 ng of
pLHN.UL54wt DNA was mixed with the oligonucleotides IRM-A (GACACG
TCGTTACAGATATCGCCTTCCTACGAGG) and IRM-B (CCTCGTAGGA
AGGCGATATCTGTAACGACGTGTC), 125 ng of each, then incubated for 1
min at 95°C, and subjected to 16 PCR cycles (30 s at 95°C, 1 min at 55°C, and 15
min at 68°C). The reaction mixtures were digested with DpnI, and the digested
DNA was transformed into Escherichia coli. Several clones were screened with
the EcoRV site, a unique restriction site introduced with the IRM mutation.
Positive clones of the new pLHN.UL54IRM plasmid were confirmed by sequenc-
ing.
PEG spheroplast fusion. The method described by Julicher et al. (12) was
followed. A yeast strain containing the YAC plasmid of interest was grown until
it reached log phase (optical density at 600 nm of 0.6 to 0.8). The cells were
washed twice with water and resuspended in SCE (1 M sorbitol, 0.1 M sodium
citrate, 60 mM EDTA [pH 7.0]), 9 mM dithiothreitol, and 100 U of lyticase/ml.
The protoplasts that formed were washed twice with SCE. Then 108 yeast
spheroplasts were fused to 2 3 106 NIH 3T3 cells in 0.5 ml of 50% polyethylene
glycol (PEG) 1500–10 mM CaCl2 for 2 min, washed with serum-free medium,
and plated. After 48 h, neomycin was added at a concentration of 400 mg/ml;
colonies appeared 2 weeks later.
Transfection and luciferase assay. NIH 3T3 cells were grown in DMEM
supplemented with 10% calf serum. Transfections were done in six-well plates,
unless otherwise noted, by the calcium phosphate precipitation method (7). For
transient transfections, cells were washed with phosphate-buffered saline 16 to
18 h after addition of the precipitate, then incubated for 24 h with 10% calf
serum supplemented medium, and finally infected with either the Towne strain
of HCMV or the Smith strain of MCMV in 3% calf serum. Stable transfections
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were done in the same way except that after the 24-h recovery in 10% calf serum
medium, cells were selected on G418 (400 mg/ml; GIBCO BRL, Gaithersburg,
Md.). Clones appeared 10 days after selection. Virus was adsorbed for 2 h prior
to the addition of fresh overlay medium.
To measure luciferase activity, the Promega luciferase assay system was used
as recommended by the manufacturer. Cells were washed twice with phosphate-
buffered saline, and 200 ml of lysis buffer (provided by the manufacturer) was
added to each well. Cells were scraped, transferred to an Eppendorf tube,
freeze-thawed, and centrifuged for 2 min. The luciferase assays were done in a
microplate luminometer (LB 96V; EG&G Berthold), using 100 ml of extract and
injecting 100 ml of luciferase substrate, with 2-s delay and 20-s reading time.
Luciferase activity is shown either as the absolute value in relative light units
(RLU), as an average of at least two experiments done in triplicate, or as fold
activation (absolute value divided by the value for corresponding mock-infected
sample).
Reverse transcriptase-mediated PCR. NIH 3T3 or HFF cells were infected
with the Towne strain of HCMV at a multiplicity of infection (MOI) of 1. Total
RNA was isolated at different times after infection by the RNAzol method
(Tel-Test, Inc., Friendswood, Tex.) according to the manufacturer’s protocol.
RNA samples were treated with RNase-free DNase I for 15 min at room tem-
perature, and the DNase was inactivated at 65°C for 15 min. The RNA was
reverse transcribed using oligo(dT) primers at 42°C for 50 min, and reactions
were terminated by heating at 70°C for 15 min. The reverse-transcribed products
were treated with RNase H for 20 min at 37°C and amplified using specific
primers. Primers IEP4BII (CAATACACTTCATCTCCTCGAAAGG) and
IEP3C (CAACGAGAACCCCGAGAAAGATGTC) were used to amplify a
217-bp product within the HCMV ie1 gene (15), and primers RTUL54-2R
(AAGCCGGCTCCAAGTGCAAGCGCC) and RTUL54-6F (CGTGTGCAAC
TACGAGGTAGCCGA) were used to amplify a 199-bp fragment within the
HCMV UL54 gene. Primers TF-R and TF-F, designed to amplify a 601-bp
product within the human tissue factor (TF) gene, and primers HPRT-R and
HPRT-F, designed to amplify a 163-bp within the murine hypoxanthine phos-
phoribosyltransferase (HPRT) gene, have been previously described (2, 16).
PCRs were performed under the following conditions: 1 cycle at 94°C for 3 min;
30 cycles of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C; and 1 cycle at 72°C
for 10 min. Control reactions carried out in the absence of reverse transcriptase
FIG. 1. (A) Transient transfection assays using 1 mg of DNA of the plasmids described, followed by infection with HCMV at an MOI of 10.
NIH 3T3 cells were lysed at different times postinfection or at the moment of infection (mock), and luciferase activity of the extracts was measured.
Relative luciferase activities from triplicate measurements are shown. The RLU values at each time postinfection are normalized to the activity
in the corresponding mock-infected cells. (B) Stably transfected clones were infected with HCMV at an MOI of 10, and samples were taken at
different times postinfection. The average RLU values from at least two experiments performed in triplicate are shown. Clones 2A-1, 2A-3, and
2A-5 are three representative clones stably transfected with pLHN.UL54wt; 6A-1, 6A-2, and 6A-4 are representative clones stably transfected with
pLHN.UL86.
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were used to assess the specific detection of RNA. Amplified products were
separated on a 1% agarose gel and visualized by ethidium bromide staining.
RESULTS
Plasmid-based analysis of HCMV UL54 promoter activity in
NIH 3T3 cells, using transient expression assays and stable
cell lines. We first used a plasmid-based transient expression
assay to investigate activation of the HCMV UL54 promoter
by HCMV in murine cells. For these experiments, a 445-bp
DNA fragment containing the UL54 promoter (nucleotide po-
sitions 80996 through 81441 in the HCMV genome) was
cloned in plasmid pLHN, to produce pLHN.UL54wt (see Ma-
terials and Methods). We also cloned a 432-bp DNA fragment
corresponding to the UL86 promoter (nucleotide positions
128318 through 128750 in the HCMV genome) into pLHN,
deriving pLHN.UL86. In these recombinants, the UL54 and
UL86 promoters drive the expression of the luciferase reporter
gene. To test if the species restriction for HCMV in murine
cells occurs at early times, each plasmid was transiently trans-
fected into NIH 3T3 cells, which were then infected with
HCMV, and luciferase activity was measured at different times
postinfection. As shown in Fig. 1A, the infection caused a
general activation of transcription, reflected by a 5-fold acti-
vation of the promoterless pGL3-basic plasmid 24 h postinfec-
tion (hpi) compared to the mock-infected sample, followed by
a 2.5-fold activation at 48 hpi. Overall activation of the UL54
promoter was slightly (sixfold) higher but similar to that for the
negative control (Fig. 1A). UL86 promoter-driven luciferase
activity responded in a similar manner (Fig. 1A). When we
tested the same plasmid in transient transfection assays in
human HFF cells, the UL54 promoter was, as expected (13),
specifically responsive to HCMV infection (data not shown).
Thus, transient expression from isolated HCMV promoters is
apparently not specifically responsive to HCMV infection in
murine cells.
To test if the nonresponsiveness of the HCMV promoters
was due to the nature of the transient assay or to the inherent
nonresponsiveness of the HCMV promoters in murine cells,
we used the same plasmids to generate neomycin-resistant
stable clones. Of the 12 neomycin-resistant UL54 promoter
clones isolated, 4 showed some luciferase activity when in-
fected with HCMV. The results for three representative clones
are shown in Fig. 1B (2A clones); the luciferase activity values
were variable, ranging from 3- to 10-fold peak activation at 24
hpi, which decreased by 48 hpi. The noninfected samples had
some residual activity in the absence of infection, most likely
influenced by the site of integration. To examine whether the
effect of HCMV infection is specific, we next investigated the
FIG. 2. Structure of the HCMV genome, showing the UL and US (unique short) regions and the inverted and direct repetitive sequences. The
STS diagram shows relative positions of the pairs of oligonucleotides used to check the integrity of HCMV. Five YACs are shown, with their
corresponding mutations outlined. The selectable markers (U, URA3; T, TRP1; L, LEU2; P, puromycin resistance; Neo, neomycin resistance) are
shown, as well as the positions of the HCMV sequences where the mutations were performed.
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expression from UL86 (late promoter) stable cell lines con-
taining plasmid pLHN.UL86. Since HCMV cannot replicate in
murine cells, we expect the UL86 promoter not to be activated
if regulation is specific, while a nonspecific enhancement would
cause some expression to be detected upon infection. In these
experiments, the UL86 neomycin-resistant clones (Fig. 1B, 6A
clones) showed no significant activation of transcription either
in the absence or in the presence of HCMV. Overall, we
conclude that the UL54 promoter, when isolated from its nat-
ural context, is poorly activated by HCMV infection in murine
cells.
Cloning and mutagenesis of an HCMV YAC. It is possible
that the lack of a robust activation of UL54 was due to inte-
gration in host chromatin and/or the lack of its natural se-
quence context. To investigate the influence of cis-acting se-
quences on the activity of the UL54 promoter in its natural
context, we constructed a YAC with a 178-kb HCMV DNA
fragment, encompassing most of the UL (unique long) region
of the viral genome (Fig. 2, Y24; for details, see Materials and
Methods). This part of the HCMV genome lacks the major IE
gene region and is expected to be defective for viral growth.
Briefly, the centromeric plasmid pRML11I2 contains a
4,895-bp DNA fragment from the 59 end of HCMV genome.
The noncentromeric plasmid pRML2(ura)1Ea has a 3,292-bp
fragment from the 39 end of the UL region. Both plasmids
were cotransformed into yeast strain YPH857 with HCMV
DNA (strain Towne). Different clones were obtained, and the
integrity of the selected YAC (Y24) was verified by several
methods. If recombination between the two plasmids and the
viral DNA is as expected, a new chromosome of around 178 kb,
encompassing the HCMV genome from the 59 end to position
178816, should be generated. Figure 3A (left) shows results of
PFGE of Y24 and of the parental strain YPH857. Y24 mi-
grates as an approximately 180-kb extra chromosome in the
stained gel. When the separated chromosomes were hybridized
to an HCMV UL54-specific probe, only Y24 showed specific
hybridization (Fig. 3A, middle).
To further test the overall integrity of the viral DNA, we
performed STS analysis with specific primer sets along the
HCMV genome. DNA was prepared from a yeast strain har-
boring Y24, and PCR was performed using six different pairs of
STS oligonucleotides specific to consecutive regions of HCMV
(locations are shown in Fig. 2; see Materials and Methods for
details). The results (Fig. 3B) show that all of the specific
primer sets amplified DNA fragments of the expected sizes
compared to the viral DNA, demonstrating the overall integ-
rity of the 178,816 bp of viral sequence.
As we wanted to use the HCMV YAC for the analysis of
essential cis-acting sequences in a transgenesis system, we next
retrofitted the YAC for selection in mammalian cells. The first
mutagenesis was targeted to the right arm of the YAC, to
introduce the puromycin resistance gene, a mammalian select-
FIG. 3. (A) PFGE to resolve different DNA samples: size markers (lane 1), YPH857 (lanes 2 and 4), Y24 (lanes 3, 5, and 6), and Y24P (lane
7). The gels were either stained with ethidium bromide (lanes 1 to 3) or hybridized to a UL54-specific probe (pol; lanes 4 and 5) or a
puromycin-specific probe (puro; lanes 6 and 7). Sizes of the marker DNA fragments are shown at the left; arrows indicate bands corresponding
to either Y24 or Y24P. (B) Agarose gel in which an aliquot of the STS PCR mixture was loaded. The lanes are marked V for AD169 DNA or Y
for YAC DNA. The set numbers for the corresponding STS, as well as locations of the size markers, are indicated. (C) PCR to test the UL54-Luc
and UL86-Luc mutations and their integration in the correct position in Y24P. The specific primers used were YAC54.2 and GLprimer2 (lanes
1 to 3), and YAC86.2 and GLprimer2 (lanes 4 and 5). The DNA samples are Y24P (lanes 1 and 4), Y24P/UL54wt-Luc (lane 2), Y24P/UL54IRM-
Luc (lane 3), and Y24P/UL86-Luc (lane 5).
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able marker. The URA3 gene was replaced by LEU2 plus the
puromycin resistance gene, using plasmid pRML2-Leu2-PUR
digested with NotI (Materials and Methods and Fig. 2). This
replacement is expected to provide a YAC with the same basic
features on the noncentromeric arm but including the mam-
malian selectable marker puromycin. Recombinant yeast
clones were selected in the corresponding medium (yeast syn-
thetic medium lacking tryptophan and leucine) and analyzed
by PFGE and Southern blot analysis. The expected 180-kb
specific band appears in the stained gel; when the puromycin
resistance gene was used as a probe in a Southern blot analysis,
only the newly made Y24P YAC gave a specific signal of
around 180 kb, indicating successful integration (Fig. 3A,
right).
To investigate the effects of cis-acting sequences on the
UL54 promoter in the context of the UL region, we con-
structed a YAC, Y24P/UL54wt-Luc, in which a luciferase re-
porter gene was inserted at position 120 of the UL54 pro-
moter (Fig. 2). The strategy was as follows. SmaI-digested
pLHN.UL54wt DNA, which contains the HIS3 gene for selec-
tion in yeast, was retrofitted into a strain containing Y24P.
Integration of the plasmid in the YAC sequence would pro-
FIG. 4. (A) Y24P/UL54wt-Luc transgenic lines were infected with HCMV at an MOI of 10. Samples were harvested at the indicated times
postinfection. Averages of at least two experiments done in triplicate are shown. As a negative control, Y24P/UL86-Luc clones 5C and 7E were
used. (B) Fold activation of luciferase activity in transgenic plasmid pLHN.UL54wt lines 2A-1, 2A-3, and 2A-5 and in Y24P/UL54wt-Luc lines 31C,
42.8, and 44.11.
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duce histidine prototrophs, in which the correct integration can
be tested by PCR. Using specific primers, directed to the re-
gion adjacent to the UL54 promoter but not included in plas-
mid pLHN.UL54wt and to the luciferase gene, a specific DNA
fragment of the expected size (1.1 kb) was amplified (Fig. 3C,
lane 2). This new YAC has, besides the UL54 promoter fused
to luciferase and integrated in its natural position in the
HCMV genome, the neomycin resistance gene, which confers
an additional marker for positive selection in mammalian cells
(Fig. 2).
In addition, as a control for HCMV L gene expression, we
constructed another YAC in which the luciferase gene was
inserted downstream of the UL86 promoter. The strategy was
very similar to the one used to generate the UL54-luciferase
(UL54-Luc) fusion, but in this case we retrofitted plasmid
pLHN.UL86, digested with SmaI, in a yeast strain harboring
Y24P (Fig. 2). The recombinant clones were selected on me-
dium lacking histidine; as described above, correct integration
was confirmed by PCR using specific primers directed to the
region neighboring the UL86 promoter and the luciferase gene
(Fig. 3C, lanes 4 and 5).
Analysis of UL54 promoter activity by stable transfer
(transgenesis) of the HCMV YAC to NIH 3T3 cells. We next
sought to examine the influence of the surrounding UL region
on UL54 transcription activity by direct transfer of Y24P/
UL54wt-Luc into NIH 3T3 fibroblasts. In these experiments,
108 yeast spheroplasts were fused to 2 3 106 mouse fibroblasts
(see Materials and Methods). After a recovery period of 48 h,
selection with neomycin (400 mg/ml) was applied and resistant
clones were isolated.
The nine neomycin-resistant clones selected were first tested
for luciferase activity after infection with HCMV at an MOI of
10. Six of these clones showed some activity in the luciferase
assays; three (clones 31C, 42.8, and 44.11) are shown in Fig. 4.
UV-inactivated virus failed to elicit a response (data not
shown), and the response of the UL54 promoter to infection in
the YAC transgenic lines was proportional to the MOI (Fig. 5).
To check the integrity of transferred YACs, we performed STS
analysis using some of the specific pairs of oligonucleotides
along the HCMV genome (see Materials and Methods). As
shown in Fig. 6, PCRs using DNA extracted from NIH 3T3
cells did not amplify any DNA fragment of the expected size.
However, DNA from both yeast strain Y24P and the transgen-
esis YAC clones showed amplified DNA fragments of the
expected sizes, indicating that intact YACs had been success-
fully transferred to NIH 3T3 cells (Fig. 6). In marked contrast
to the plasmid transgenic lines (Fig. 4A), the YAC-containing
NIH 3T3 cells showed very low luciferase activity when mock
infected; 24 h after infection with HCMV, they exhibited a very
strong upregulation, which continued to increase up to 48 h
(Fig. 4A). Furthermore, the absolute values of luciferase ac-
tivity in the stable YAC clones were less variable and consis-
tently higher than for the stable plasmid-containing cell lines.
The basal reporter gene levels in mock-infected YAC trans-
genic cells are subject to a highly specific and very tight regu-
lation. Comparison between the plasmid and the transgenesis
cell lines showed very strong activation of the UL54 promoter
upon HCMV infection, ranging from 170 at 24 hpi to 470-fold
at 48 hpi in the YAC cell lines (Fig. 4B). This level of activation
is much higher than in the stable plasmid clones, suggesting a
positive influence of remote viral DNA sequences in addition
to more stringent regulation prior to activation. It is notewor-
thy that the second peak of activation at 48 h is not observed
with the plasmid transgenic lines.
Transgenesis experiments were also carried out with Y24P/
UL86 in murine cells. The UL86 promoter is a true L promoter
(4), being activated only after the onset of DNA replication.
The transfer yielded three neomycin-resistant clones, and the
presence of the YAC sequences was tested by Southern blot-
ting and STS analysis (data not shown). None of these clones
showed any luciferase activity before or after infection with
HCMV (Fig. 4A, clones 5C and 7E). The lack of activation of
UL86 transcription in the transgenesis experiments indicates
the expected restriction in replication of HCMV in murine
cells. Altogether, these results underscore the importance of
sequence context in providing an optimal level of gene expres-
sion.
Analysis of the UL54 promoter activation pathway by
HCMV in murine cells. The primary pathway for early activa-
tion of the UL54 promoter is dependent on IE86-mediated
activation via the IR1 element that binds the cellular transcrip-
tion factor Sp1. To investigate the early activation pathway of
HCMV UL54 in murine cells, we accordingly mutated the IR1
element present in the UL54 promoter (13). Figure 2 shows
the point mutations introduced in the IR1 site, which has been
FIG. 5. The stable NIH 3T3 line containing Y24P/UL54wt-Luc
clone 44.11 was infected with HCMV at MOIs from 0.005 to 10. Cells
were harvested at 48 hpi, and luciferase activity was measured. Each
point represents the average of two independent infections.
FIG. 6. STS analysis of YAC transgenic NIH 3T3 clones. PCRs
were performed using specific primer sets designed along the HCMV
genome (see Materials and Methods). DNA from NIH 3T3 cells (lanes
1, 4, 7, 10, and 13), yeast Y24P positive control (lanes 2, 5, 8, 11, and
14), or NIH 3T3 cells expressing Y24P/UL54wt-luc clone 44.11 (lanes
3, 6, 9, 12, and 15) was used, along with different sets of primers as
indicated at the top.
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previously shown to completely eliminate IE86 transactivation
of the UL54 promoter (14).
In agreement with previous studies, mutant plasmid
pLHN.UL54IRM showed a much lower activation after trans-
fection in HFF cells and infection with HCMV (around 17-fold
reduction) compared to the wt counterpart (data not shown)
(13). On the basis of this result, we next retrofitted plasmid
pLHN.UL54IRM into Y24P, to study the effect of the IRM
mutation in the UL54 promoter in the context of the UL
region. Figure 2 shows a schematic of the recombinant gener-
ated in yeast (Y24P/UL54IRM-Luc), and its integrity was con-
firmed by PFGE, STS analysis, and Southern blot hybridization
(not shown). We next performed transgenesis studies by
spheroplast fusion of Y24P/UL54IRM-Luc to NIH 3T3 cells.
The PEG fusion produced eight neomycin-resistant clones,
three of which showed luciferase activity after infection with
HCMV (Fig. 7). The profile of activation, with a peak at 24 h,
was different from that for the UL54 wt promoter (compare
Fig. 4B and 7), but most significantly, both the absolute values
(not shown) and the extent of activation (10- to 30-fold [Fig.
7]), were significantly diminished. The remaining activity is
most likely due to the ATF binding site positioned upstream of
the IR-Sp1 element of the UL54 promoter (13). These results
suggest that the pathway used for HCMV early activation of
the UL54 promoter is conserved in murine cells and that the
same or functionally similar cellular factors bind to the UL54
promoter. In agreement with this view, we observe IE1 and
UL54 RNA upon infection of NIH 3T3 cells with HCMV (Fig.
8). From these experiments, we conclude that HCMV early
activation of the UL54 promoter by IE transactivators is not
restricted by host species-encoded cellular factors.
Analysis of MCMV activation of the HCMV UL54 promoter
in YAC transgenic clones. In the experiments described above,
we maintained a homologous promoter-virus relationship in a
heterologous host cell background and demonstrated that the
activation of E gene expression uses the same cellular pathway
in both human and murine cells. Knowing that the cellular
pathway is conserved between human and murine cells, we
next sought to test the effect of changing the species origin of
the virus. For these experiments we infected the YAC trans-
genic clones Y24P/UL54wt-Luc 31C and 44.11 with MCMV
and examined their levels of activation of the UL54 promoter.
In this scenario, the cell-virus relationship is homologous (both
are murine), while the promoter-virus relationship is heterol-
ogous.
We infected the two Y24P/UL54wt-Luc clones with MCMV
at an MOI of 10 and determined luciferase activity at 24 and 48
hpi. The maximum transcriptional activity by MCMV was 10-
fold lower than the activation by HCMV (Fig. 4B and 9, clones
31C and 44.11). This lower activation implicates restriction at
a viral trans-acting factor level, necessitating the concordance
of species origin of both promoter and viral transactivators to
recapitulate the activation profile of the UL54 promoter. As
anticipated, the Y24P/UL86-Luc 5C and 7C clones were not
activated by MCMV infection (Fig. 9). Taken together, these
results suggest that there is a dominance of virus over host
factors in determining the species specificity of E gene expres-
sion.
DISCUSSION
CMV is a pathogen with a highly restricted spectrum of
hosts. HCMV shows a very strong species specificity, being
FIG. 7. Stable Y24P/UL54IRM-Luc-containing NIH 3T3 clones
were infected with HCMV at an MOI of 10. Samples were harvested
at the indicated times, and luciferase activity determined as indicated
in Materials and Methods. Each point represents the average of at
least two independent experiments done in triplicate. Fold activation
was calculated by dividing the absolute value by the mock-infected
value. Results for three representative clones are shown.
FIG. 8. Detection of HCMV IE1 and UL54 transcripts in 3T3 cells
infected with HCMV. NIH 3T3 or HFF cells were mock infected (M)
or infected with HCMV at an MOI of 1. Total RNA was harvested at
different times (hours postinfection) indicated, treated with DNase,
and reverse transcribed by using oligo(dT). PCRs were performed
using primer sets specific for HCMV IE1 UL54, human TF (for HFF
samples), and murine HPRT (for NIH 3T3 samples) as described in
Materials and Methods. Amplified products were separated on 1%
agarose gels and visualized by ethidium bromide staining. Amplified
fragments obtained in the different reactions are shown. Sizes were as
expected for each primer set (see Materials and Methods for details).
Specific PCR-amplified products were not detected in control reac-
tions in which reverse transcriptase was not added during the RNA
reverse transcription reaction (data not shown).
FIG. 9. Y24P/UL54wt-Luc-containing NIH 3T3 clones were in-
fected with MCMV at an MOI of 10. Samples were harvested at the
indicated times, and luciferase activity measured. Each point repre-
sents the average of at least two independent experiments done in
triplicate. Fold activation was calculated by dividing the absolute value
by the mock-infected value. Results for two representative clones are
shown.
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able to replicate only in human cells. HCMV can efficiently
enter cells of other species, indicating that the species restric-
tion is not at the level of viral binding or penetration (21).
Recent studies have provided direct evidence that major IE
expression determined by viral IE regulatory sequences is also
not species restricted (3, 8). In the present study we show that
an essential E gene activation pathway governed by HCMV
major IE proteins is conserved between host species. However,
we observed a marked divergence in the mechanism for this
activation between viral species.
We used a YAC transgenesis approach to examine the spe-
cies restriction checkpoint of an essential E gene activation
pathway of HCMV in murine cells. The YAC vectors have
advantages over other conventional vectors like plasmids and
cosmids: they allow the manipulation of larger fragments of
DNA, and the genetic manipulations can be accurately and
easily performed in yeast. Toward this end, we designed a YAC
vector encompassing most of the UL region of HCMV. This
vector is replication defective, lacks the major IE region, and
thus permits the analysis of essential cis-acting sequences
within the UL region when complemented in trans. For the
purpose of this study, we chose to study essential cis-acting
sequences of the viral DNA polymerase (UL54) promoter
complemented by HCMV infection in murine cells. The iso-
lated UL54 promoter, in both transient and stable transfec-
tions of murine cells, showed a profile of activation not con-
sistent with an E gene. Only when in the context of the UL
region was the UL54 promoter able to recapitulate the early
(48 hpi) gene activation described for human cells (13). To
avoid variability, we used the same plasmids for the transfec-
tion assays and for the YAC mutagenesis. In the UL54wt
plasmid stable clones, the basal activity in mock-infected cells
was not as tightly regulated as in the YAC clones, and the
extent and profile of activation were more random. This sug-
gests the need for tight regulation of early events, and perhaps
the involvement of long-range cis-acting sequences (sequence
context) for optimal UL54 gene regulation. Indeed, the results
of this study strongly support the suggestion that remote reg-
ulatory sequences participate in the control of expression of
this essential E gene.
Members of the CMV family have evolved by cospeciation
with their host and as a consequence have had sufficient time
to acquire a significant degree of genetic drift (19). In partic-
ular, the genetics of HCMV speciation has led to nonviable
replication in other host species. In this case we can assume
that genetic changes that have been beneficial or neutral in its
natural host background may well be deleterious in another
host genetic background because of negative or inappropriate
gene interactions that had not been screened by natural selec-
tion. For this reason, species-specific strains of CMV must
have accumulated genetic changes that may be advantageous
or neutral in its host species but lethal in other species. The
results of this study suggest that the virus-host gene interaction
pathway for E gene activation is viable between different host
species but has significantly diverged between virus species.
This strongly argues for coevolution of viral trans-acting factors
and their viral target promoters. In agreement, mutation of the
IR1 element of the HCMV UL54 promoter showed that the
pathway of E activation is the same in human and murine cells.
Thus, IE86-mediated activation of UL54 via IR1 is conserved
in murine cells. In support, the primary host factor known to
bind IR1 is Sp1, in which sequence homology between human
and murine Sp1 is over 95%. In contrast, the MCMV transac-
tivator IE3 not only exhibits more sequence differences (,40%
identity) from its related HCMV IE86 counterpart but also is
extremely inefficient at activating the HCMV UL54 promoter
via IR1, indicating a divergence of mechanism of action. A
prediction from these observations is that it would not be
informative to study HCMV IE proteins in the context of
MCMV infection. Consistent with this notion, we find that an
IE3 mutant of MCMV is poorly complemented by HCMV
infection in murine cells (A. Angulo and P. Ghazal, unpub-
lished results).
In summary, we have used a YAC transgenesis system to
explore critical host-virus gene interaction pathways in the
cross-species activation of a key E gene promoter of HCMV,
UL54. Our results show a clear dominance of virus factors
(major IE proteins) for transactivation of the UL54 early pro-
moter and evidence for a species specificity checkpoint at later
times of infection. Whether the species barrier can be crossed
remains an open question.
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